文献速递痛风与晶体性关节病

痛风随机试验的结局报告:来自OMERACT痛风工作组的系统范围综述评估核心结局集的采纳情况

Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set.
PubMed 文献 · Semin Arthritis Rheum · 2023-03-15

该系统范围综述检索多个数据库及临床试验注册平台,纳入71项痛风随机对照试验(36项急性发作试验、35项慢性降尿酸试验),评估其报告是否符合2009年OMERACT核心结局域。结果显示仅3/36项(8%)急性试验报告全部5个核心域,慢性试验无一报告全部7个核心域,且测量工具差异大,患者重要域报告率低。结论认为对核心结局域的依从性低,需持续鼓励研究者遵循OMERACT核心域并进一步指导结局测量报告。

要点

  • 仅3/36项(8%)急性痛风试验报告全部5个核心域,慢性试验无一报告全部7个核心域。
  • 慢性试验中血清尿酸报告率100%、痛风发作80%,但其他核心域报告率<30%。
  • 患者重要域如健康相关生活质量、患者总体评估和活动受限极少报告。

核心结论

  • 急性和慢性痛风研究对OMERACT认可的核心结局域依从性低,表明全球OMERACT关于临床试验最低测量内容的努力采纳不佳。
  • OMERACT认可的核心结局域的测量方式存在显著差异。
  • 该系统综述表明需要持续鼓励痛风研究者遵循OMERACT核心域,并进一步指导结局测量报告。

研究设计与样本

  • 系统范围综述,检索PubMed、EMBASE、Cochrane Library(含CENTRAL和CDSR)及ClinicalTrials.gov,无日期限制。
  • 纳入分配痛风患者至活性药物治疗或对照的随机对照试验,共纳入71项试验,其中急性试验36项、慢性试验35项。
  • 急性试验指描述痛风发作短期管理干预的研究,慢性试验指描述长期降尿酸治疗管理痛风的研究。
  • 注册号:Prospero CRD42019151316。

主要发现

  • 数据库检索识别8522条记录,审查134篇全文,最终纳入71项试验。
  • 仅3/36项(8%)急性试验报告全部5个核心域,35项慢性试验中无一报告全部7个核心域。
  • 急性试验的5个核心域共识别27种独特测量工具;慢性试验的7个核心域共使用31种独特测量工具。
  • 慢性试验中血清尿酸报告率100%,痛风发作报告率80%,其他核心域报告率<30%。
  • 患者重要域如健康相关生活质量、患者总体评估和活动受限极少报告;少数试验使用OMERACT认可的测量工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The selection and reporting of core outcome measures in clinical trials is essential for patients, researchers, and healthcare providers for clinical research to have an impact on healthcare. In this systematic scoping review, we aimed to quantify the extent to which gout clinical trials are collecting and reporting data in accordance with the core outcome domains from Outcome Measures in Rheumatology (OMERACT) published in 2009 applicable for both acute and chronic trials and evaluate the reporting according to the core domains before and after the 2009 OMERACT endorsement. METHODS: We searched multiple databases PubMed, EMBASE, the Cochrane Library including the Cochrane Central Register of Controlled Trials (CENTRAL), and Cochrane Database of Systematic Reviews (CDSR) and www. CLINICALTRIALS: gov for randomized controlled trials (RCTs) allocating people with gout versus an active pharmacological gout treatment or a control comparator (no date limitation). We extracted the data in accordance with the core outcome sets, focusing individually on core outcome domains and the core outcome measurements for acute and chronic trials, respectively. In this study 'Acute trials' reflect studies that describe interventions for short term management of gout flares, and 'chronic trials' describe interventions for long-term urate lowering therapy in the management of gout. RESULTS: From 8,522 records identified in the database search, 134 full text papers were reviewed, and 71 trials were included, of which 36 were acute and 35 were chronic. Only 3 of 36 (8%) acute trials reported all five core domains and none of the 35 included chronic trials reported all 7 core domains. In the acute trials, twenty-seven unique measurement instruments across the 5 core domains were identified. For chronic trials there were 31 unique measurement instruments used across the 7 core domains. Serum urate was reported in 100% of the chronic trials and gout flares in 80%. However, other core domains were reported in <30% of chronic trials. In particular the patient-important domains such as HR-QOL, patient global assessment and activity limitations were rarely reported. A broad variety of different measurement instruments were used to assess each endorsed core domain, a minority of trials used the OMERACT endorsed instruments. For acute trials, the number reporting on all core domains was consistently low and no change was detected before and after the endorsement of the core domains in 2009. None of the included chronic trials reported on all 7 endorsed core domains at any time. CONCLUSION: In this study we found a low adherence with the intended endorsed (i.e., core) outcome domains for acute and chronic gout studies which represents a poor uptake of the global OMERACT efforts for the minimum of what should be measured in clinical trials. In addition, there is a significant variation in how the OMERACT endorsed outcome domains have been measured. This systematic review demonstrates the need for continuous encouragement among gout researchers to adhere to OMERACT core domains as well as further guidance on outcome measurements reporting. REGISTRATION: Prospero: CRD42019151316.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Morillon MB, Nørup A, Singh JA, et al. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set. Semin Arthritis Rheum. 2023. PMID: 36963128. doi:10.1016/j.semarthrit.2023.152191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。